(AOF) – Maat Pharma announces that as of June 30, 2023, its total cash and cash equivalents amounted to 35.1 million euros, compared to 35.2 million euros as of December 31, 2022. biotech, a specialist in the restoration of the microbiota/host symbiosis in cancer patients, estimates that it has sufficient cash flow to cover the needs of development programs “until the second quarter of 2024”. The net loss for the first half stood at 8.43 million euros compared to 7.41 million a year ago.
Half-year turnover increased from 494,000 euros to 1.37 million over the period, reflecting “the increase in requests from doctors and the treatment of a larger number of patients”.
“During the first half of 2023, we laid solid foundations for our clinical development and industrial scale-up of production,” said Siân Crouzet, Administrative and Financial Director of MaaT Pharma. “Regarding MaaT013, our most advanced product in hemato-oncology, the lifting of the FDA suspension and the upcoming DSMB review for our Phase 3 trial represent pivotal steps in our development,” he said. she adds.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
